top of page

GLP-1 telehealth programs: how to plan lab testing and monitoring

5 days ago
5 min read
Flat illustration of a telehealth dashboard on a laptop, an unbranded injection pen, an open at-home lab kit and a rack of blood specimen tubes beside a lab analyzer, in navy, lavender and pink

A GLP-1 telehealth program needs a lab plan built around the prescribing information, not a one-size panel. Most programs order baseline labs to confirm eligibility and spot conditions such as type 2 diabetes, then retest at set points and whenever symptoms suggest a problem, with clear rules for who reviews results and how fast.


That's the short answer. The rest of this guide is for telehealth platforms, weight-management programs and metabolic health brands working out what lab testing their GLP-1 service needs and how to run it smoothly. It's operational guidance, not medical advice: what to order for any patient is always the prescribing clinician's call.



Why lab work matters in GLP-1 programs


GLP-1 and dual GIP/GLP-1 medicines such as semaglutide (Wegovy) and tirzepatide (Zepbound) are prescription drugs with detailed FDA labeling. Neither label sets a fixed lab schedule for every patient, but both describe situations where lab results shape care. That makes testing part of how a program stays safe and defensible, not an add-on.


Labs also help with things payers, partners and patients ask about: whether someone has diabetes or prediabetes, how their cardiometabolic markers change over time, and whether a program can show outcomes beyond the number on a scale.



What the prescribing information says about labs


A few points from the current labels are worth building into your protocols. Always check the latest version, since both labels were revised in 2026.


  • Kidney function: both the Wegovy prescribing information and the Zepbound prescribing information warn about acute kidney injury from volume depletion and say to monitor renal function in patients who report gastrointestinal side effects that could lead to dehydration, especially while the dose is being started or increased.

  • Thyroid monitoring: the Wegovy label says routine serum calcitonin monitoring is of uncertain value for early detection of medullary thyroid carcinoma and can lead to unnecessary procedures. So calcitonin is not a default panel item; it's ordered when a clinician has a reason.

  • Pancreatic enzymes: the Zepbound label notes mean increases in amylase and lipase in trials, with unknown clinical significance in the absence of other signs of pancreatitis. Routine enzyme testing without symptoms can create noise your clinicians then have to explain.

  • Glucose-lowering medicines: both labels warn that combining these drugs with insulin or an insulin secretagogue raises the risk of hypoglycemia. Patients with diabetes on those medicines usually need closer glucose monitoring.

  • Pregnancy: the Wegovy label says to stop at least 2 months before a planned pregnancy when used for weight reduction, and the Zepbound label advises patients on oral hormonal contraceptives to switch methods or add a barrier method for 4 weeks after starting and after each dose increase. Pregnancy testing policy is a clinical decision, but it should be written down.

  • Other medicines: both labels say delayed gastric emptying can affect oral medicines, and suggest considering more clinical or lab monitoring for drugs with a narrow therapeutic index.



A practical baseline panel


Programs differ, but baseline testing usually aims to answer three questions: is this patient a good candidate, are there conditions the clinician needs to know about, and what will we compare against later?


For diabetes screening, the USPSTF recommends screening adults aged 35 to 70 who have overweight or obesity for prediabetes and type 2 diabetes. Since most GLP-1 weight-management patients fall in that group, an HbA1c or fasting glucose test is a common baseline item.


Beyond that, many programs consider:


  • A metabolic panel with kidney function (creatinine and eGFR), electrolytes and liver enzymes, which gives a reference point if dehydration or other problems come up later.

  • A lipid panel, since cardiometabolic risk is often part of why patients seek treatment and why programs track outcomes.

  • Thyroid function (TSH), which some clinicians order when weight change or symptoms suggest it.

  • Pregnancy testing where your clinical protocol calls for it.


Keep the panel focused. Every extra test adds cost, more results to review, and more chances for an incidental finding your team has to follow up on.



Planning follow-up testing


Follow-up testing usually falls into two groups.



Scheduled retests


Many programs repeat HbA1c and a lipid panel at set intervals so they can show change over time and give clinicians a reason to adjust the plan. Pick intervals your clinical leads agree on and build them into the patient journey, so retest kits or orders go out automatically rather than depending on someone remembering.



Triggered testing


Some testing should happen because something changed, not because a date arrived. Based on the labels, the clearest example is a kidney function check when a patient reports vomiting, diarrhea or other signs of dehydration during dose escalation. Write these triggers into your protocols, along with who orders the test and how fast results need to come back.



How collection fits a telehealth model


GLP-1 programs are mostly virtual, so the collection method matters as much as the test menu.


  • At-home kits work well for patients who are far from a draw site, and for scheduled retests where convenience keeps people in the program. Not every test can be done this way, so check each marker against what the lab has validated for home-collected samples.

  • In-person draws may be needed for some tests or larger panels. If you use them, make sure the order, the patient's location and the lab's coverage all line up.

  • State coverage matters. Your ordering clinicians need to be licensed where patients live, and the lab needs to be able to accept specimens from those states.


If you're mapping out the full patient journey, our guide to telehealth consultations with home lab kits walks through each step from order to results review.



Results routing and clinical follow-up


The lab work is only as useful as what happens next. Before launch, decide:


  • Who reviews results, and within what time frame for normal, abnormal and critical values.

  • How critical values reach a clinician at any hour, not just a shared inbox.

  • What patients see and when, including plain-language explanations of out-of-range results.

  • When a result pauses treatment, such as a kidney function change or a new diabetes diagnosis that changes the care plan.


Under CLIA, the lab must send results to the authorized person who ordered the test, so make sure your ordering provider setup and your results integration agree on where reports go.



Questions to ask a GLP-1 lab partner


When comparing lab partners for a GLP-1 program, ask:


  1. Which of the markers you need are validated for at-home collection, and which need a venous draw?

  2. Is the lab CLIA-certified, and which state licenses does it hold?

  3. Can kits be white-labeled and shipped directly to patients?

  4. How do orders and results move: portal, API or both?

  5. How are critical values communicated, and to whom?

  6. What turnaround should you expect, and how is it measured?

  7. Can the lab support scheduled retest kits without manual orders each time?


IHDLab works with telehealth and metabolic health programs as a CLIA-certified lab partner, with white-label at-home kits and order and results options described on our telehealth lab partner page. We don't prescribe medication; we provide the testing behind your clinicians' decisions.



The bottom line


A good GLP-1 lab plan is short, label-informed and written down: a focused baseline panel, scheduled retests that run automatically, clear triggers for extra testing, and fast results routing to the clinician who ordered them. Get those pieces right before launch, and lab work becomes a strength of your program rather than a bottleneck.

bottom of page